Article Text

Download PDFPDF
The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis
  1. SC Davison*,
  2. NM Hyman*,
  3. A Dehghan,
  4. K Chan
  1. *Department of Neurology, Radcliffe Infirmary, Oxford,
  2. The School of Pharmacy, Liverpool Polytechnic, Liverpool†


    The relationship between plasma levels of pyridostigmine to clinical evaluation of muscle power was examined in nine patients with myasthenia gravis during treatment with pyridostigmine in doses of 60 to 1040 mg daily. Five of the nine subjects demonstrated a trend towards a positive correlation, but in only two of them was this statistically significant at p < 0.05. In addition, the presence or absence of a possible correlation between muscle power and plasma concentration was not related to the duration of the disease, additional prednisolone therapy or thymectomy.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.